Dr Dennis Kim - MD
Associate Professor,
Faculty of Medicine, University of Toronto
Staff Physician/Clinical Investigator,
Department of Medical Oncology & Hematology,
Princess Margaret Hospital
Toronto, Ontario

“Hidden Advances and Remaining Challenges in CML”

Wednesday, November 9, 2016
Glen – Cedars Cancer Centre 08:30 to 09:30
Room D02.1312
Hôpital Notre-Dame 17:00 to 18:00
Amphithéâtre Deschamps

Live on the Web!
www.vpsolution.tv/vspo
Problems/Questions: 514 813-4510

Learning Objectives
• Discuss relevant findings of the PMH CML database in regards to patient management and outcome after TKI therapy
• Exchange on the evolving treatment goals of CML and their clinical implications on patients and physicians’ clinical practice
• Best practice sharing in the management and treatment optimization of sub-optimal CML responders and pre-transplant patients (Case base discussion)

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visiting speakers.asp

This program has received an educational grant from:
Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche